Surrozen (SRZN) director awarded 5,550 options at $30.14 exercise price
Rhea-AI Filing Summary
Surrozen director Mary Haak‑Frendscho received a grant of 5,550 stock options. These Director Stock Options give her the right to buy 5,550 shares of Surrozen common stock at an exercise price of $30.14 per share. The options vest on the anniversary of the May 13, 2026 grant date, as long as she continues serving as a director, and will expire on May 12, 2036 if not exercised.
Positive
- None.
Negative
- None.
Insights
Routine director option grant with long-dated vesting and standard service condition.
Director Mary Haak‑Frendscho was granted 5,550 Director Stock Options for Surrozen common stock. The exercise price is $30.14 per share, with a final expiration on May 12, 2036. This is classified as a grant or award, not an open‑market purchase or sale.
The footnote states the options vest on the anniversary of the grant date, contingent on continuous board service. Such time‑based vesting is typical for non‑employee directors and aligns incentives with longer‑term company performance without immediate cash outlay by the company.
After this grant, the filing shows 5,550 derivative securities held, with no additional option positions listed. Future company filings may clarify any subsequent equity awards or exercises that change her overall equity exposure.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (right to buy) | 5,550 | $0.00 | $0.00 |
Footnotes (1)
- F1. The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.
Key Figures
Key Terms
Director Stock Option financial
grant/award acquisition financial
exercise price financial
derivative securities financial
vesting financial
AI-generated analysis. How Rhea-AI works. Not financial advice.